Open Access Research Article
EXPLORING COMPULSORY LICENSING IN THE BIOTECHNOLOGY SECTOR: BALANCING INNOVATION, ACCESS, AND ETHICAL CONSIDERATIONS AND ITS ALIGNMENT WITH THE BROADER PRINCIPLES OF THE DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH WITH RESPECT TO HIV/AIDS
Published Paper
Article Details
EXPLORING COMPULSORY LICENSING IN THE BIOTECHNOLOGY SECTOR:
BALANCING INNOVATION, ACCESS, AND ETHICAL CONSIDERATIONS AND ITS ALIGNMENT WITH
THE BROADER PRINCIPLES OF THE DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH WITH RESPECT TO HIV/AIDS
AUTHORED BY - KEERTHI NARENDRAN
ABSTRACT:
The use of compulsory licensing to
manage public health emergencies is at the forefront of current discussions as
the relationship between intellectual property rights (IPR) and public health
continues to drive worldwide policy debates. The Doha Declaration on TRIPS and
Public Health played a crucial role in influencing the discourse, and this
research paper explores the complex interplay between these subjects.
Compulsory licensing, a mechanism entrenched within international trade
agreements such as the Trade-Related Aspects of Intellectual Property Rights
(TRIPS), offers a complex approach to reconciling IPR protection and the
imperative of ensuring timely access to essential medicines. Nevertheless, this
mechanism is not immune to potential loopholes and challenges that may impact
its effectiveness. The paper scrutinises these potential pitfalls, including
the scope, duration, and criteria for issuing compulsory licenses and the
broader implications of trade tensions and diplomatic relations. The Doha Declaration
on TRIPS and Public Health is central to the analysis, a pivotal turning point
in the evolution of global IPR discourse. This landmark declaration
acknowledges the primacy of public health interests and facilitates flexibility
in implementing TRIPS provisions to safeguard access to medicines for all. The
study emphasises the Doha Declaration's crucial influence in defining the moral
and legal parameters of forced licensing, particularly in responding to public
health emergencies. Through a comprehensive examination of case studies and
policy developments, the paper illuminates the practical application of
compulsory licensing and its resonance with the principles espoused in the Doha
Declaration. It explores the delicate balance between intellectual property
protection and the fundamental human right to health, shedding light on the
intricate negotiations and considerations that underscore the decision-making
process. Ultimately, this research paper provides a multidimensional
understanding of the intricate relationship between compulsory licensing, the
Doha Declaration on TRIPS and Public Health, and the broader landscape of
intellectual property and global health. By shedding light on the potential
loopholes inherent in compulsory licensing and contextualising its
implementation within the framework of the Doha Declaration, the paper
contributes to informed policy discourse aimed at fostering innovation,
safeguarding public health, and achieving equitable access to essential
medicines on a global scale.
KEYWORDS:
Public health, compulsory licensing,
Doha declaration, TRIPS
INTRODUCTION:
Access to medicines is
a highly debated issue in intellectual property. To provide further access
would mean the companies have to give the licenses to their patents to help
manufacture on a grander scale. Another problem is that of compulsory
licensing.
Compulsory licensing is
a legal mechanism that allows governments to grant licenses to third parties to
produce and sell patented pharmaceuticals without the patent holder's consent.
This is typically done in public health emergencies or when the patented drugs
are unaffordable or unavailable to a significant portion of the population.
Advocates of compulsory
licensing argue that it is a crucial tool for ensuring access to life-saving
medicines, particularly in developing countries where the cost of patented
drugs can be prohibitively high. They contend that compulsory licensing can help
address public health crises by making essential medications more affordable
and accessible.
The central debate
revolves around whether compulsory licensing negatively affects
biotechnological innovation. Critics argue that it may disincentivise companies
from investing in research and development if they fear that their patents
could be subject to compulsory licensing. This argument suggests that weakening
intellectual property protections may hinder the development of innovations.
International trade agreements,
such as the Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS), set guidelines for compulsory licensing. Countries must adhere to
these guidelines when issuing compulsory licenses to ensure that they are used
for legitimate public health purposes and that patent holders receive adequate
compensation.[1]
In this paper, the
authors will examine how compulsory licenses will benefit access to life-saving
drugs for those affected with HIV/AIDS. Further, they will be analysing the
current legislation in India to examine the applicability of compulsory
licensing for this purpose.
HISTORICAL TRENDS IN THE USA AND
CANADA:
In the 1960s, the United States
frequently used "government use" to import pharmaceuticals,
indicating compulsory licensing for pharmaceutical access. On the other hand,
Canada employed compulsory licensing for pharmaceutical imports and local
production to manage healthcare expenditures. As early as 1923, the Canadian
government amended the Patent Act to encourage domestic pharmaceutical
manufacturing and market competition through compulsory licensing. By the
1960s, public concerns about high pharmaceutical prices prompted significant
amendments to the Patent Act, allowing compulsory licensing for the manufacture
or import of previously restricted pharmaceuticals. These measures in Canada
resulted in increased market competition, with several follow-on drugs entering
the pharmaceutical market.
The United States and Canada have
historically employed compulsory licensing to address pharmaceutical
accessibility, affordability, and competition, reflecting the evolving dynamics
of pharmaceutical regulation and healthcare expenditure management.
THE BENEFICIARIES:
The debate is
particularly between high-income countries and low and middle-income countries
(LMICs). The primary argument favouring compulsory licensing is rooted in the
need to make essential medicines more affordable and accessible, especially in
LMICs, to improve public health outcomes. This approach is aligned with public
health and humanitarian principles, as demonstrated by the Doha Declaration,
which reaffirmed the right of World Trade Organization (WTO) member countries
to issue compulsory licenses for public health reasons. Compulsory licensing is
seen as a counterbalance to the robust protection of intellectual property
rights, particularly in high-income countries, and is considered necessary to
address the potential negative consequences of excessive intellectual property
rights on innovation in the pharmaceutical industry. The debate over compulsory
licensing revolves around balancing incentivising innovation and ensuring
access to essential medicines.
Low- and
middle-income countries (LMIC) argued that they needed compulsory for their
citizens. The drugs were costly, whereas high-income countries feared that
extensive issuance of compulsory licenses could have adverse consequences for
the pharmaceutical industry, particularly in terms of its profitability and
long-term research and development capabilities. The crux of their argument
rested on the notion that limiting the exclusive rights of patent holders
through compulsory licensing might discourage innovation by reducing the
financial incentives for pharmaceutical companies to invest in research and
development efforts. This concern about striking a balance between promoting
access to medicines and fostering innovation in the pharmaceutical sector has
been at the heart of the international debate on intellectual property rights
and compulsory licensing.[2]
It must also be
considered that branded or patented medicines are often expensive due to the
lack of competition. Since only one drug like that is available everywhere,
they are unaffordable for many people,[3]
especially in low and middle-income countries where the burden of this disease
is often the highest.[4]
Further,
patients with HIV/AIDS are ostracised in most societies. They have difficulties
in obtaining regular medicines. To them, if a specific medicine is available at
a lower cost through compulsory licensing, it could save their life.
WHY SHOULD COMPULSORY LICENSING BE
ALLOWED:
“Patents motivate companies to
engage in capital-intensive and inherently risky biomedical research because of
the possibility of charging monopoly prices and reaping high profits. On the
other hand, that very monopoly prevents generic manufacturing and affects the
price and availability of the finished medicine to consumers. A successful
intellectual property regime must strike a balance between creating incentives
for innovation and protecting consumers' access to essential medicine."[5]
This is a standard set of arguments
regarding compulsory licensing where the perspectives of society and the
manufacturers are given.
There are several reasons why it is
beneficial for society. The Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS) allows countries to issue compulsory licenses for
public health reasons. Some countries have invoked this provision to produce or
import generic versions of patented HIV/AIDS drugs, thereby reducing costs and
increasing availability.[6] The debate around compulsory licensing for
HIV/AIDS medications is centred on the balance between protecting intellectual
property rights and ensuring access to essential medicines. Advocates argue
that compulsory licensing is necessary to address public health crises, while
opponents contend that it may discourage pharmaceutical innovation.
It provides for Access to
Antiretroviral Drugs. Compulsory licensing has been considered to increase access
to antiretroviral drugs (ARVs) used to treat HIV/AIDS. Some countries,
particularly those with high HIV/AIDS prevalence and limited resources, have
explored compulsory licensing to ensure affordable access to these life-saving
medications.[7]
Various global initiatives, such as
the Medicines Patent Pool, have aimed to facilitate access to essential
medicines, including ARVs, through voluntary licensing agreements with
pharmaceutical companies. These initiatives seek to strike a balance between
ensuring access and protecting intellectual property.[8]
The application of compulsory
licensing for HIV/AIDS drugs varies by country and context. It depends on
factors like the prevalence of HIV/AIDS, the availability of affordable
treatments, and the willingness of pharmaceutical companies to negotiate
pricing and licensing agreements.[9] Developing
countries argue that their distinct economic, public health, and developmental
challenges necessitate flexibilities in intellectual property regimes,
particularly regarding compulsory licensing for HIV/AIDS medications. These
nations face significant economic disparities and limited resources, making it
challenging to afford essential healthcare services and life-saving treatments.
In severe public health challenges, such as the high prevalence of HIV/AIDS,
ensuring access to affordable medicines takes precedence over protecting
intellectual property rights. Developing countries emphasise the need for
tailored solutions that safeguard public health and foster innovation. They
also utilise TRIPS flexibilities to protect public health and argue that
innovation should not hinder access to essential medicines. These countries aim
to address their healthcare needs effectively through compulsory licensing
while respecting international trade agreements.
WORLD HEALTH ORGANISATION (WHO) AND
THE DOHA DECLARATION:
The WHO has a long recognized the
importance of the agreement on Trade related aspects of intellectual property
rights (TRIPS) in shaping the global intellectual property landscapes for
medicines. [10]TRIPS
was a significant concern for the WHO because it required member countries to
provide patent protection for Pharmaceuticals.
The WHO played a central role in the
DOHA Declaration on the TRIPS Agreement and public health which was adopted in
2001. This declaration affirmed the right of countries to take measures to
protect public health and promote access to medicine. It clarified that TRIPS
should not prevent countries from taking action to address public health crisis
like HIV/AIDS.
The Doha Declaration also explicitly
recognized the important of compulsory licensing as one of the flexibilities
provided by TRIPS. Compulsory licensing allows a country to grant licensing to
generic manufacturers to produce patented medicines without the consent of the
patent holder, under certain conditions.
The WHO has consistently advocated for
equitable access to essential medicines as a fundamental human right. This
includes access to antiretroviral drugs (ARVs) for HIV/AIDS treatment and drugs
for hepatitis.[11] The
organization has encouraged countries to implement policies that facilitate access
to these medicines. The WHO has also provided technical assistance and guidance
to countries on how to use TRIPS flexibilities effectively, including
compulsory licensing, to enhance access to medicines. This assistance includes
legal and technical support to countries in navigating the intellectual
property landscape.[12]
INDIAN CONTEXT:
In the case of Novartis
AG v Union of India,[13]
by providing a detailed background, including the specific patent application
and Novartis's legal arguments, along with the reasons for the patent rejection
by the Indian authorities. It may delve into the relevant provisions of the
Indian patent law, particularly section 3(d) of the Indian Patent Act, which
sets strict criteria for patentability, especially in pharmaceutical
innovations. The article may discuss legal and ethical considerations regarding
intellectual property rights and access to essential medicines. It also
discusses the potential long-term ramifications of the Novartis case on patent
law in India and its influence on future legal battles and policies related to
pharmaceutical patents.
TRIPS flexibilities
enable compulsory licensing for public health reasons, while global
initiatives, market competition, and partnerships further enhance access to
medications. Moreover, public funding for research and development and
prioritising public health interests in emergencies contribute to a comprehensive
strategy for effectively combating HIV/AIDS while fostering innovation in the
pharmaceutical industry.
A similar approach was
tested in Kenya, and it was found that the specific legislation was created to
make licenses for patents stringent. This would increase the high death toll of
HIV/AIDS in Kenya. It is a lesson that India should be aware of during policy
discussions.[14]
In India, the utilisation
of patents and compulsory licensing holds immense significance in the context
of HIV/AIDS. India struggles with a substantial burden of HIV/AIDS, and
ensuring access to affordable and effective treatments is a critical public
health imperative. The country's diverse population includes economically
disadvantaged communities, underscoring the vital importance of medication
affordability.
CONCLUSION:
To address the challenges
posed by HIV/AIDS, involving patents and compulsory licensing is vital. Patents
serve as incentives for pharmaceutical innovation, encouraging companies to
develop new and improved treatments. However, when patented HIV/AIDS
medications become excessively expensive and hinder access, compulsory
licensing can be employed judiciously to authorise generic drug production.
This facilitates affordability and broadens access to patients. Striking the
balance between protecting intellectual property rights and ensuring public
health is crucial. India's robust generic pharmaceutical industry has earned it
the moniker "Pharmacy of the developing world," primarily due to its
compulsory licensing grants that allow it to produce and distribute
cost-effective generic versions of HIV/AIDS medication. The Indian Patents Act,
featuring provisions like section 3(d) and flexibility in issuing compulsory
licenses for public health reasons, provides a legal framework that enables the
government to balance intellectual property rights with the urgent need for
accessible medicines. Compulsory licensing has been essential in improving
access to life-saving HIV/AIDS treatment and setting an international example,
contributing to global discussions on patent protection and public health.
India's prioritisation of public health and stringent intellectual property
enforcement in emergencies underscores its commitment to combat HIV/AIDS
effectively.
[1]Berman D, AIDS, Essential
Medicines, and Compulsory Licensing., 54 J INT ASSOC PHYSICIANS AIDS CARE. 24-5. (1999)
[2] Kyung-Bok
Son, Importance Of The Intellectual Property System In Attempting
Compulsory Licensing Of Pharmaceuticals: A Cross-Sectional Analysis, (June
27, 2019),
https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-019-0485-7.
[3] Urias E, Ramani SV. Access to medicines after
TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A
review of the existing evidence. 3(4): J INT BUS POLICY 367–84 2020.
[4] Zaidel, EJ, Inclusion In
The World Health Organization Model List Of Essential Medicines Of Non-Vitamin
K Anticoagulants For Treatment Of Non-Valvular Atrial Fibrillation: A Step
Towards Reducing The Burden Of Cardiovascular Morbidity And Mortality, vol.
15, no. 1 GLOBAL HEART 52 2020
[5] Linda
L. Lee, Trials and TRIPS-Regulations: Indian Patent Law and Novartis AG v.
Union of India Vol. 23, No. 1, ANNUAL REVIEW OF LAW AND TECHNOLOGY (2008),
pp. 281-313
[6] Ndlovu, Precious N. Has
Doha Achieved Its Mandate regarding Access to Essential Medicines? a Developing
World’s Perspective. 2009
[8] Sherer, Mark, Prognostic
Importance of Self-Reported Traits/Problems/Strengths and Environmental
Barriers/Facilitators for Predicting Participation Outcomes in Persons With
Traumatic Brain Injury: A Systematic Review. ARCHIVES OF PHYSICAL MEDICINE
AND REHABILITATION, 2014,
[10] Hays, Thomas S. The
Free Movement (or Not) of Trademark Protected Goods in Europe. Edward Elgar
Publishing EBooks, 2008
[12] WHO, Access To Affordable Medicines for HIV/AIDS and Hepatitis: The
Intellectual Property Rights Context
[14] See
Ben Sihanya, Patents, Parallel
Importation and Compulsory Licensing of HIV/AIDS Drugs: The Experience of
Kenya, WTO
Article Information
EXPLORING COMPULSORY LICENSING IN THE BIOTECHNOLOGY SECTOR: BALANCING INNOVATION, ACCESS, AND ETHICAL CONSIDERATIONS AND ITS ALIGNMENT WITH THE BROADER PRINCIPLES OF THE DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH WITH RESPECT TO HIV/AIDS
Authors: KEERTHI NARENDRAN
- Journal IJLRA
- ISSN 2582-6433
- Published 2024/04/18
- Issue 7
About Journal
International Journal for Legal Research and Analysis
- Abbreviation IJLRA
- ISSN 2582-6433
- Access Open Access
- License CC 4.0
All research articles published in International Journal for Legal Research and Analysis are open access and available to read, download and share, subject to proper citation of the original work.
Disclaimer: The opinions expressed in this publication are those of the authors and do not necessarily reflect the views of International Journal for Legal Research and Analysis.